Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged â ¥75 years) with overactive bladder syndrome

BJU International

Volumn 107, Issue 4, 2011, Pages 612-620

  Sand, Peter K ^a   Johnson Ii, Theodore M ^a   Rovner, Eric S ^b   Ellsworth, Pamela I ^c   Oefelein, Michael G ^d   Staskin, David R ^e  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c BROWN UNIVERSITY   (United States)

^d ALLERGAN INC   (United States)

^e TUFTS UNIVERSITY   (United States)

Author keywords

elderly; overactive bladder syndrome; trospium chloride

Indexed keywords

PLACEBO; TROSPIUM CHLORIDE;

ABDOMINAL DISTENSION; ADULT; AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RELEASE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY THROAT; FEMALE; FLATULENCE; HUMAN; KIDNEY PAIN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERACTIVE BLADDER; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STOMACH DISCOMFORT; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINE INCONTINENCE; URINE RETENTION; VERTIGO;

AGED; AGED, 80 AND OVER; DELAYED-ACTION PREPARATIONS; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MUSCARINIC ANTAGONISTS; NORTROPANES; PATIENT SATISFACTION; QUALITY OF LIFE; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE;

EID: 79551543569     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09519.x     Document Type: Article

References (40)

1. Griebling TL, Kraus SR, Richter HE, Glasser DB, Carlsson M,. Tolterodine extended release is well tolerated in older subjects. Int J Clin Pract 2009; 63: 1198-204
2. Foote J, Glavind K, Kralidis G, Wyndaele JJ,. Treatment of overactive bladder in the older patient; pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Eur Urol 2005; 48: 471-7
3. Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004; 93: 303-10
4. Zinner NR, Mattiasson A, Stanton SL,. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc 2002; 50: 799-807
5. Thom DH, Haan MN, Van Den Eeden SK,. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality. Age Ageing 1997; 26: 367-74
6. Sand P, Zinner N, Newman D, et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder; a multicentre, community-based, randomized study. BJU Int 2007; 99: 836-44
7. Brown KE,. Multidisciplinary Medication Management Project. Top Ten Dangerous Drug Interactions in Long-Term Care. Available at:. Accessed May 2009
8. Han L, Agostini JV, Allore HG,. Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc 2008; 56: 2203-10
9. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults; evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56: M146-56
10. Miles TP, Palmer RF, Espino DV, Mouton CP, Lichtenstein MJ, Markides KS,. New-onset incontinence and markers of frailty: data from the Hispanic Established Populations for Epidemiologic Studies of the Elderly. J Gerontol A Biol Sci Med Sci 2001; 56: M19-24
11. Holroyd-Leduc JM, Mehta KM, Covinsky KE,. Urinary incontinence and its association with death, nursing home admission, and functional decline. J Am Geriatr Soc 2004; 52: 712-8
12. Mooradian AD,. Effect of aging on the blood-brain barrier. Neurobiol Aging 1988; 9: 31-9
13. Kay GG, Abou-Donia MB, Messer WS Jr, Murphy DG, Tsao JW, Ouslander JG,. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 2005; 53: 2195-201
14. Ancelin ML, Artero S, Portet F, Dupuy AM, Touchon J, Ritchie K,. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs; longitudinal cohort study. BMJ 2006; 332: 455-9
15. Scheife R, Takeda M,. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther 2005; 27: 144-53
16. Dmochowski RR, Sand PK, Zinner NR, Staskin DR,. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology 2008; 71: 449-54
17. Staskin D, Sand P, Zinner N, Dmochowski R, Trospium Study Group. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder; results from a multicenter phase III trial. J Urol 2007; 178: 978-83
18. Nixon A, Colman S, Sabounjian L, et al. A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol 2005; 174: 604-7
19. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S,. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997; 104: 1374-9
20. Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire; the OAB-q. Qual Life Res 2002; 11: 563-74
21. Kelleher CJ, Pleil AM, Reese PR, Burgess SM, Brodish PH,. How much is enough and who says so? BJOG 2004; 111: 605-12
22. Staskin DR, Rosenberg MT, Sand PK, Zinner NR, Dmochowski RR,. Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome; an integrated analysis of two randomised, phase III trials. Int J Clin Pract 2009; 63: 1715-23
23. Abrams P, Malone-Lee J, Jacquetin B, et al. Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine. Drugs Aging 2001; 18: 551-60 (Pubitemid 32664728)
24. Haab F, Corcos J, Siami P, et al. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int 2006; 98: 1025-32
25. Haab F, Cardozo L, Chapple C, Ridder AM,. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005; 47: 376-84
26. Appell R, Anderson R, Gittelman M,. Efficacy, safety and tolerability of once-daily oxybutynin in elderly patients. J Am Geriatr Soc 2000; 48: S81
27. Wagg A, Wyndaele JJ, Sieber P,. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome; a pooled analysis. Am J Geriatr Pharmacother 2006; 4: 14-24
28. Allergan, Inc. Data on file
29. Rovner E, Dmochowski R, Watanabe J,. Once daily trospium chloride 60 mg extended release is safe and effective in patients with the overactive bladder syndrome who use multiple concomitant medications. Neurourol Urodyn 2009; 28: 146-7
30. Andersson KE, Olshansky B,. Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. BJU Int 2007; 100: 1007-14
31. Andersson KE, Sarawate C, Kahler KH, Stanley EL, Kulkarni AS,. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. BJU Int 2010; 106: 268-74
32. Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006; 50: 317-26
33. Sandage B, Lerch G, Larsen G, Profy A,. Trospium chloride does not cross the blood-brain barrier of male Long Evans rats. Neurology 2009; 72 (Suppl. 3): A50
34. Geyer J, Gavrilova O, Petzinger E,. The role of p-glycoprotein in limiting brain penetration of the peripherally acting anticholinergic overactive bladder drug trospium chloride. Drug Metab Dispos 2009; 37: 1371-4
35. Bolge SC, Cerulli A, Kahler KH, Gause D,. Impact of successful treatment of overactive bladder on health care resource use and productivity. Drug Benefit Trends 2006; 18: 244-55
36. Brown JS, Vittinghoff E, Wyman JF, et al. Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc 2000; 48: 721-5
37. Darkow T, Fontes CL, Williamson TE,. Costs associated with the management of overactive bladder and related comorbidities. Pharmacotherapy 2005; 25: 511-19
38. Neubauer DN,. Sleep problems in the elderly. Am Fam Physician 1999; 59: 2551-8
39. Stone KL, Ancoli-Israel S, Blackwell T, et al. Actigraphy-measured sleep characteristics and risk of falls in older women. Arch Intern Med 2008; 168: 1768-75
40. Isik AT, Celik T, Bozoglu E, Doruk H,. Trospium and cognition in patients with late onset Alzheimer disease. J Nutr Health Aging 2009; 13: 672-6